Asset Pipeline

Our Asset Pipeline

We are engaged in the pursuit of drug therapies for the treatment of onychomycosis and herpes zoster opthalmicus. Market-ready and 510k pending assets include management tools for advanced wound care and dermatitis.

Hexagen
AtopX
Antimicrobial Saturated Gauze
Onychomycosis
Herpes Zoster Opthalmicus
Preclinical
Clinical Trials
FDA Filing
Commercial
Preclinical
Clinical Trials
FDA Filing
Commercial